Clinical and Translational Oncology

, Volume 15, Issue 12, pp 1018–1024 | Cite as

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

Clinical Guides in Oncology

Abstract

Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab.

Keywords

Head and neck cancer Induction chemotherapy TPF Cetuximab EXTREME ERBITAX 

Notes

Conflict of interest

The authors declare that they have no conflict of interest relating to the publication of this manuscript.

References

  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality in Europe: estimates for 40 countries in 2012. Eur J Cancer (online version). 2013. doi: 10.1016/j.ejca.2012.12.027.
  2. 2.
    TNM Classification. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.Google Scholar
  3. 3.
    Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890–900.PubMedCrossRefGoogle Scholar
  4. 4.
    Winquist E, Oliver T, Gilvert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck. 2007;29:38–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer. Lancet. 2000;355:949–55.PubMedGoogle Scholar
  6. 6.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesía R, Degardin M, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. Phase III trial EORTC 24971/TAX 323. NEJM. 2007;357:1695–704.PubMedCrossRefGoogle Scholar
  9. 9.
    Posner MR, Hershock DM, Blajman CR, Michiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. TAX 324 Study Group. NEJM. 2007;357:1705–25.PubMedCrossRefGoogle Scholar
  10. 10.
    Lefebvre JL, And KK. Larynx preservation clinical trial design: key issues and recommendations. A consensus panel summary. Int J Radiation Oncol Biol Phys. 2009;73:1293–303.Google Scholar
  11. 11.
    VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Departament of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685–90.Google Scholar
  12. 12.
    Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31:845–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Pointreau Y, Garuad P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer. 2009;101:498–506.Google Scholar
  15. 15.
    Bonner JA, Harari M, Giralt J, Baselga J, Shin D, Cohen R et al. Improved preservation of larynx with the addition of cetuximab to radiotherapy for cancers of the larynx and hypopharynx. J Clin Oncol. 2005;23(16S):5533.Google Scholar
  16. 16.
    Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.Google Scholar
  19. 19.
    Hitt R, Irigoyen A, Cortes Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • R. Mesía
    • 1
  • M. Pastor
    • 2
  • J. J. Grau
    • 3
  • E. del Barco
    • 4
  1. 1.Servicio de Oncología MédicaInstitut Català d’Oncologia-L’HopsitaletBarcelonaSpain
  2. 2.Servicio de Oncología MédicaHospital General Universitario La FeValenciaSpain
  3. 3.Servicio de Oncología MédicaHospital Clinic deBarcelonaSpain
  4. 4.Servicio de Oncología MédicaHospital Universitario de SalamancaSalamancaSpain

Personalised recommendations